Project Grant R21AG119774
- The National Institute on Aging awarded the University of Kansas Medical Center Research Institute, Inc. $312,736 on March 1, 2026 under the Aging Research program (CFDA 93.866) to investigate the association between body composition, physical activity, and cognitive function in adults with Down syndrome. The research examines how obesity and moderate-to-vigorous physical activity relate to cognitive outcomes in adults with Down syndrome, who face approximately a 90 percent lifetime risk for...
- The National Institutes of Health Office of the Director awarded Ann & Robert H Lurie Children's Hospital of Chicago $448,860 on August 21, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to co-design a digital care pathway that improves primary care clinician adherence to pediatric Down syndrome health supervision guidelines. The project will develop a scalable digital pathway to facilitate clinician implementation of evidence-based Down syndrome screening, early treatment,...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $980,965 to Montclair State University on August 13, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct a project grant investigating spatial navigation as a domain-specific marker of cognitive decline in adults with Down syndrome. The research will recruit 40 adults with Down syndrome ages 35–50 to examine whether and how spatial navigation impairments relate to...
- The National Institutes of Health Office of the Director awarded University of California Irvine $6.132 million on August 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the neurobiological basis for cognitive dysfunction and dementia in aging adults with Down syndrome. The project uses spatial multi-omics techniques—combining transcriptomics, epigenomics, and proteomics—to analyze over 100 clinically characterized brain samples from individuals with Down...
- The National Institutes of Health Office of the Director awarded $2.693 million to the University of Wisconsin–Madison on September 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to establish an Alzheimer's disease biomarker clock in Down syndrome using positron emission tomography and plasma analytes. The research addresses the underrepresentation of individuals with Down syndrome in Alzheimer's disease therapeutic trials by characterizing biomarker progression in this...
- The National Institutes of Health Office of the Director awarded the University of New Mexico Health Sciences Center $419,375 on July 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate mechanisms of vascular dysfunction in Down syndrome. The research examines endothelial dysfunction and glycocalyx depletion in a mouse model of Down syndrome (TCMAC21 mice) to understand cardiovascular disease risk in the Down syndrome population. The study investigates how...
- The National Institute of Child Health and Human Development awarded Trustees of Boston University $131,694 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to characterize neural correlates of motor skill development in children with Down syndrome. The research uses upper extremity reaching as a model motor behavior to identify associations between reaching kinematics and brain activity in two pediatric cohorts. During the two-year...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded the University of Wisconsin System $568,615 on September 2, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the molecular mechanisms underlying synaptic deficiency in Down syndrome. The research project, titled "Molecular Mechanisms Underlying Synaptic Deficiency in Down Syndrome" (R01HD120347), will use isogenic trisomy 21 disorder-specific human...
- The National Institutes of Health Office of the Director awarded the University of Southern California $462,951 on July 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to measure real-world stepping and walking performance in infants and toddlers with Down syndrome. The award funds validation of accelerometer-based wearable step-counting devices for infants with Down syndrome, addressing a gap in clinical measurement tools. The project will establish the accuracy of step...
- The National Institute on Aging awarded The Washington University $406,707 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct a national longitudinal study examining whether integrated dual-eligible special needs plans improve health outcomes for adults with intellectual disabilities and dementia who are dually enrolled in Medicare and Medicaid. The study addresses the absence of national research on dementia care access, quality, and outcomes among...
The National Institutes of Health Office of the Director awarded the University of Kansas Medical Center Research Institute, Inc. $439,467 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop and refine PUZZLEWALK 2.0, a gamified mobile health application designed to promote physical activity and cognitive training in adults with Down syndrome. The project will enhance the existing PUZZLEWALK app through user-centered design involving adults with Down syndrome. Work includes refining the activity detection algorithm, adding cognitive training activities to supplement existing spot-the-difference puzzles, and aligning the app with usability, design, and functionality preferences of the target population. The team will assess usability of the current PUZZLEWALK version in 20 adults with Down syndrome using eye-tracking technology, system usability scales, objective app-based metrics, and interviews. A community advisory board comprising 5 people living with Down syndrome and their caregivers will participate in focus groups and beta testing to inform PUZZLEWALK 2.0 development. The underlying clinical goal is to build cognitive reserve and potentially delay Alzheimer's disease symptoms, given that individuals with Down syndrome face over 90 percent lifetime risk of Alzheimer's disease. Performance will occur in Kansas City, Kansas. The period of performance runs through July 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $439.5k | 8/12/26 |